{"id":"lenvatinib-plus-tace","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Hypertension"},{"rate":"35-45","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Decreased appetite"},{"rate":"20-30","effect":"Nausea"},{"rate":"20-30","effect":"Proteinuria"},{"rate":"15-25","effect":"Weight loss"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL1289601","moleculeType":"Small molecule","molecularWeight":"426.86"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and other kinases involved in tumor angiogenesis and proliferation. When combined with TACE—a minimally invasive procedure that delivers chemotherapy directly into the hepatic artery feeding the tumor while blocking blood supply—the two modalities work synergistically to enhance local tumor control and systemic anti-angiogenic effects in hepatocellular carcinoma.","oneSentence":"Lenvatinib inhibits multiple receptor tyrosine kinases to suppress tumor angiogenesis and growth, combined with TACE (transarterial chemoembolization) to deliver chemotherapy directly to hepatic tumors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:30.452Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC) in combination with transarterial chemoembolization"}]},"trialDetails":[{"nctId":"NCT07487662","phase":"PHASE2","title":"TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-18","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":105},{"nctId":"NCT07480382","phase":"NA","title":"Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC","status":"NOT_YET_RECRUITING","sponsor":"Hong Wu","startDate":"2026-04-01","conditions":"Initially Unresectable Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT07417800","phase":"NA","title":"Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"Hepatocellular Carcinoma (HCC), Artificial Intelligent, Adjuvant Chemoradiotherapy","enrollment":1000},{"nctId":"NCT07408804","phase":"NA","title":"Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Bangladesh Medical University","startDate":"2025-04-08","conditions":"Unresectable Hepatocellular Carcinoma (HCC)","enrollment":40},{"nctId":"NCT07350070","phase":"PHASE2","title":"TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-31","conditions":"HCC, Liver Cirrhosis, Portal Hypertension","enrollment":78},{"nctId":"NCT07340502","phase":"","title":"TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-31","conditions":"HCC","enrollment":364},{"nctId":"NCT04246177","phase":"PHASE3","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-22","conditions":"Carcinoma, Hepatocellular","enrollment":480},{"nctId":"NCT07157969","phase":"PHASE2","title":"ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-02-19","conditions":"HCC - Hepatocellular Carcinoma","enrollment":300},{"nctId":"NCT07156617","phase":"","title":"A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-10-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":2000},{"nctId":"NCT07150377","phase":"PHASE2","title":"A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Shandong First Medical University","startDate":"2025-08-24","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":41},{"nctId":"NCT07099274","phase":"PHASE2","title":"Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-08-22","conditions":"HCC","enrollment":29},{"nctId":"NCT04997850","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Xinrui Zhu，MD","startDate":"2020-10-01","conditions":"Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor","enrollment":142},{"nctId":"NCT06794073","phase":"NA","title":"Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-09-01","conditions":"Carcinoma, Hepatocellular, Neoplasms, Glandular and Epithelial, Adenocarcinoma","enrollment":17},{"nctId":"NCT07131501","phase":"PHASE2","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-11","conditions":"Hepatocellular Carcinoma, Immunotherapy, Preoperative","enrollment":48},{"nctId":"NCT06740370","phase":"NA","title":"TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-13","conditions":"Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Anti-PD1 Antibody","enrollment":32},{"nctId":"NCT07052448","phase":"","title":"The Efficacy of Sequential RT After Triple Therapy for uHCC","status":"ENROLLING_BY_INVITATION","sponsor":"Fujian Provincial Hospital","startDate":"2020-11-01","conditions":"Hepatocellular Carcinoma","enrollment":35},{"nctId":"NCT06643208","phase":"","title":"D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-07-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":37},{"nctId":"NCT05660213","phase":"","title":"A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":750},{"nctId":"NCT06904196","phase":"PHASE2","title":"Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-04-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":78},{"nctId":"NCT06904183","phase":"PHASE2","title":"Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-04-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":320},{"nctId":"NCT06916546","phase":"","title":"SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-06-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":238},{"nctId":"NCT05901194","phase":"PHASE1, PHASE2","title":"Lenvatinib Treatment in Waiting List of Liver Transplantation After TACE Failure in Patients With Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-07-10","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":25},{"nctId":"NCT06896396","phase":"PHASE1, PHASE2","title":"Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhiyong Huang","startDate":"2025-04-01","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05319431","phase":"PHASE2","title":"A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-28","conditions":"Unresectable, Non-metastatic Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT06371157","phase":"PHASE3","title":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-08-02","conditions":"Hepatocellular Carcinoma","enrollment":469},{"nctId":"NCT05920863","phase":"PHASE2","title":"Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-07-01","conditions":"Hepatocellular Carcinoma, Lenvatinib, Tislelizumab","enrollment":35},{"nctId":"NCT06492395","phase":"PHASE3","title":"Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":178},{"nctId":"NCT05301842","phase":"PHASE3","title":"Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-03-28","conditions":"Hepatocellular Carcinoma","enrollment":760},{"nctId":"NCT06762782","phase":"PHASE2","title":"Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-02","conditions":"Hepatocellular Carcinoma (HCC), Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) At High Risk of Recurrence After Curative Resection or Ablation","enrollment":276},{"nctId":"NCT06609850","phase":"NA","title":"The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-10-01","conditions":"Recurrent Hepatocellular Carcinoma, Lenvatinib, Local Therapy","enrollment":116},{"nctId":"NCT06643533","phase":"","title":"Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)","status":"NOT_YET_RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2025-01-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":15},{"nctId":"NCT06602011","phase":"","title":"Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-09-30","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT06561399","phase":"","title":"Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)","status":"RECRUITING","sponsor":"Fujian Provincial Hospital","startDate":"2024-08-15","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":28},{"nctId":"NCT06470256","phase":"PHASE1","title":"Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Zhiyong Huang","startDate":"2024-06-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT05717738","phase":"","title":"Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2022-01-20","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":300},{"nctId":"NCT05738616","phase":"PHASE3","title":"Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)","status":"RECRUITING","sponsor":"Wen Tianfu","startDate":"2024-05-10","conditions":"Advanced Hepatocellular Carcinoma","enrollment":196},{"nctId":"NCT06265883","phase":"","title":"Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2019-07-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":205},{"nctId":"NCT06261138","phase":"","title":"Survival Analysis: TACE vs. Combination Therapy in HCC","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma","enrollment":279},{"nctId":"NCT05842317","phase":"PHASE1, PHASE2","title":"Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-09-01","conditions":"Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT06205732","phase":"","title":"A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.","status":"UNKNOWN","sponsor":"Qianfoshan Hospital","startDate":"2024-01-01","conditions":"Carcinoma, Hepatocellular","enrollment":100},{"nctId":"NCT06194695","phase":"","title":"DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Ze-yang Ding, MD","startDate":"2022-02-01","conditions":"Cholangiocarcinoma Non-resectable","enrollment":100},{"nctId":"NCT06192784","phase":"PHASE2","title":"Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2023-12-09","conditions":"Cholangiocarcinoma Non-resectable","enrollment":36},{"nctId":"NCT06003673","phase":"PHASE4","title":"A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Fujian Medical University","startDate":"2023-07-01","conditions":"Hepatocellular Carcinoma Resectable","enrollment":20},{"nctId":"NCT06089382","phase":"PHASE3","title":"A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-11-01","conditions":"Hepatocellular Carcinoma","enrollment":104},{"nctId":"NCT05250843","phase":"PHASE2, PHASE3","title":"TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-05-30","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT05985798","phase":"PHASE3","title":"Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2023-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":258},{"nctId":"NCT05903456","phase":"PHASE2","title":"Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-07","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT05608200","phase":"PHASE3","title":"Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-11-02","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":427},{"nctId":"NCT04967495","phase":"NA","title":"TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-07-09","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":171},{"nctId":"NCT05592197","phase":"NA","title":"Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2018-10-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT05718232","phase":"PHASE3","title":"SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03","conditions":"Advanced Hepatocellular Carcinoma","enrollment":136},{"nctId":"NCT04911959","phase":"PHASE1, PHASE2","title":"Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-07-01","conditions":"Hepatocellular Carcinoma, Lenvatinib","enrollment":50},{"nctId":"NCT05131698","phase":"EARLY_PHASE1","title":"Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Cancer Hospital of Guangxi Medical University","startDate":"2021-03-01","conditions":"Tislelizumab, Lenvatinib, TACE","enrollment":31},{"nctId":"NCT05332496","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT05332821","phase":"","title":"TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":474},{"nctId":"NCT04599790","phase":"PHASE2","title":"TACE Combined With Lenvatinib and Sintilimab for Advanced HCC","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2020-10-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":30},{"nctId":"NCT05608213","phase":"PHASE3","title":"Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-11-02","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":187},{"nctId":"NCT05582278","phase":"PHASE2","title":"HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC","status":"UNKNOWN","sponsor":"Wen Li","startDate":"2021-01-01","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05582109","phase":"PHASE2","title":"Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-10-30","conditions":"Objective Response Rate (ORR)","enrollment":30},{"nctId":"NCT05555316","phase":"PHASE2","title":"TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-11-10","conditions":"Liver Tumor","enrollment":46},{"nctId":"NCT05171335","phase":"PHASE2","title":"Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients","status":"ENROLLING_BY_INVITATION","sponsor":"The Methodist Hospital Research Institute","startDate":"2022-06-20","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT05535998","phase":"","title":"TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT","status":"COMPLETED","sponsor":"Yunfei Yuan","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":743},{"nctId":"NCT05307926","phase":"","title":"Postoperative Adjuvant Therapy of HCC Based on PD-1","status":"COMPLETED","sponsor":"Chen Xiaoping","startDate":"2019-02-01","conditions":"Hepatocellular Carcinoma, RFS","enrollment":573},{"nctId":"NCT04974281","phase":"EARLY_PHASE1","title":"PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT03838796","phase":"NA","title":"Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-01-03","conditions":"Hepatocellular Carcinoma","enrollment":297},{"nctId":"NCT05420922","phase":"","title":"Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-11-01","conditions":"Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy","enrollment":2000},{"nctId":"NCT05220020","phase":"PHASE3","title":"TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-05-18","conditions":"Hepatocellular Carcinoma","enrollment":299},{"nctId":"NCT05247996","phase":"NA","title":"TACE Combined With \"Target Immune\" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-03-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":98},{"nctId":"NCT05135364","phase":"PHASE2","title":"HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure","status":"UNKNOWN","sponsor":"Yue Han","startDate":"2021-11-05","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":48},{"nctId":"NCT05056337","phase":"PHASE3","title":"Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08-01","conditions":"Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT04490694","phase":"PHASE2","title":"TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-03-01","conditions":"Hepatocellular Carcinoma","enrollment":54},{"nctId":"NCT04814043","phase":"PHASE2","title":"PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-04-20","conditions":"Hepatocellular Carcinoma","enrollment":57},{"nctId":"NCT04531228","phase":"NA","title":"TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial","status":"UNKNOWN","sponsor":"Yunfei Yuan","startDate":"2020-10-11","conditions":"Hepatocellular Carcinoma, Transarterial Chemoembolization","enrollment":60},{"nctId":"NCT05042336","phase":"PHASE1, PHASE2","title":"The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2021-09-01","conditions":"Carrelizumab Plus Lenvatinib Combined With TACE, Borderline Resectable Hepatocellular Carcinoma","enrollment":49},{"nctId":"NCT04127396","phase":"PHASE4","title":"Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2019-09-01","conditions":"Carcinoma, Hepatocellular, Portal Vein Tumor Thrombus","enrollment":72},{"nctId":"NCT04961138","phase":"NA","title":"Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08","conditions":"Hepatocellular Carcinoma Stage III","enrollment":164},{"nctId":"NCT04909866","phase":"PHASE2, PHASE3","title":"The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-01-01","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT04229355","phase":"PHASE3","title":"DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2021-02-02","conditions":"Hepatocellular Carcinoma","enrollment":90},{"nctId":"NCT04317248","phase":"PHASE2","title":"\"Cocktail\" Therapy for Hepatitis B Related Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Yuehua Huang","startDate":"2020-04-01","conditions":"Hepatocellular Carcinoma","enrollment":600},{"nctId":"NCT04560751","phase":"","title":"TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2020-09-30","conditions":"Carcinoma, Hepatocellular","enrollment":300},{"nctId":"NCT04273100","phase":"PHASE2","title":"PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-11-14","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":56},{"nctId":"NCT03905967","phase":"PHASE3","title":"TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-06-16","conditions":"Advanced Hepatocellular Carcinoma","enrollment":336},{"nctId":"NCT03791918","phase":"PHASE3","title":"Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2019-01-01","conditions":"Hepatocellular Carcinoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":163,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lenvatinib plus TACE","genericName":"Lenvatinib plus TACE","companyName":"Second Affiliated Hospital of Guangzhou Medical University","companyId":"second-affiliated-hospital-of-guangzhou-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenvatinib is a small molecule used in combination with Transarterial chemoembolization (TACE) for the treatment of unresectable advanced Hepatocellular Carcinoma (HCC). This combination treatment is being studied in clinical trials, such as NCT04599790, for its efficacy in treating HCC conditions including non-resectable HCC and portal vein tumor thrombus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}